|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S1
|
$50,000
|
$50,000
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Novel Glyco-tests to Predict Chemoresistance
|
3R43CA213766-01A1S2
|
$149,785
|
$149,785
|
RAZI, NAHID
|
ACCUDAVA, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$36,461
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inhibition of Senescence to Increase Cancer Cell Death: A New Paradigm
|
5R01CA077263-19
|
$417,500
|
$137,775
|
MCDAID, HAYLEY
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PNNL Proteome Characterization Center
|
5U24CA210955-03
|
$1,063,923
|
$351,095
|
LIU, TAO
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
Novel therapeutics for targeting checkpoint dysfunction in cancer
|
5R01CA203824-02
|
$362,569
|
$90,642
|
LIN, WEEI-CHIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$2,378
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$5,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$2,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$64,062
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
$336,565
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
iPGDAC, An Integrative Proteogenomic Data Analysis Center for CPTAC
|
5U24CA210954-03
|
$973,045
|
$330,835
|
ZHANG, BING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Discovery and Characterization of Mutations in Breast and Ovarian Cancers
|
5R50CA211280-03
|
$215,047
|
$107,524
|
ADAMSON, AARON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
3R01CA197359-04S1
|
$68,577
|
$68,577
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell/Nanoparticle Constructs for Targeted Ovarian Cancer Therapy
|
5R01CA197359-04
|
$388,875
|
$388,875
|
BERLIN, JACOB
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
$43,750
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
$754,172
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$76,296
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$25,950
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$1,313
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular Mechanisms of BRCA1-Dependent DNA Damage Response and Tumorogenesis
|
5R01CA132755-11
|
$382,500
|
$126,225
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Functional analysis of BRCA1 in DNA damage response and tumor suppression
|
5R01CA187209-05
|
$352,750
|
$176,375
|
YU, XIAOCHUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Analysis of BRCA1 Recombination Functions
|
5R01CA095175-14
|
$328,700
|
$164,350
|
SCULLY, RALPH
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Parallel and high throughput isolation of cancer cell derived extracellular vesicles
|
1R43CA232848-01
|
$239,138
|
$119,569
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cancer Deep Phenotype Extraction from Electronic Medical Records
|
5U24CA184407-06
|
$993,015
|
$327,695
|
SAVOVA, GUERGANA
|
BOSTON CHILDREN'S HOSPITAL
|
|
A Follow-up Study for Causes of Cancer in Black Women
|
5U01CA164974-08
|
$3,131,894
|
$313,189
|
ROSENBERG, LYNN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Enzyme-instructed self-assembly for molecular anticancer nanomedicines
|
5R01CA142746-09
|
$368,145
|
$368,145
|
XU, BING
|
BRANDEIS UNIVERSITY
|
|
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression
|
5R35CA197605-03
|
$966,086
|
$966,086
|
CRAMER, DANIEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Clinical Evaluation of an Implantable Lab-in-a-patient microdevice that measures in-situ response to therapies in advanced ovarian cancer
|
1R21CA216796-01A1
|
$183,736
|
$183,736
|
JONAS, OLIVER
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Interplay of mammary luminal cells and environmental factors in establishing p53-deficient premalignant field
|
1R01CA222560-01
|
$374,766
|
$187,383
|
LI, ZHE
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dietary and Hormonal Determinants of Cancer in Women
|
5P01CA087969-19
|
$2,402,014
|
$600,504
|
STAMPFER, MEIR
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Redefining Normal: personalized CA125 cutpoints for ovarian cancer screening
|
5R01CA193965-03
|
$371,704
|
$371,704
|
TERRY, KATHRYN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer
|
5R01CA197780-03
|
$363,581
|
$363,581
|
DIFEO, ANALISA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
$56,380
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-28S1
|
$249,965
|
$2,500
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Contribution of Gynecologic and Breast Cancer Biospecimens from African American women to HCMI
|
3P30CA043703-28S2
|
$48,000
|
$480
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-05
|
$1,187,291
|
$118,729
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
3R01CA211707-02S1
|
$149,945
|
$149,945
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
Functional Effects of Ovarian Cancer Risk Variants
|
5R01CA211707-02
|
$622,079
|
$622,079
|
GAYTHER, SIMON
|
CEDARS-SINAI MEDICAL CENTER
|
|
The Role of Splice Quantitative Traits in Ovarian Cancer Pathogenesis
|
5R21CA220078-02
|
$181,178
|
$181,178
|
LAWRENSON, KATE
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B Cells I Solid Malignancies - Diversity Supplement
|
3R01CA208753-03S1
|
$106,651
|
$106,651
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
|
5R01CA208753-03
|
$400,313
|
$400,313
|
ORSULIC, SANDRA
|
CEDARS-SINAI MEDICAL CENTER
|
|
Early Detection of Ovarian Cancer Through Epigenetic Factors in the WHI
|
5R01CA204119-03
|
$415,462
|
$415,462
|
GENKINGER, JEANINE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Evaluating Notch Signaling as a Therapeutic Target in Ovarian Cancer
|
5F31CA192891-05
|
$49,524
|
$49,524
|
PRICE, JESSICA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S1
|
$120,000
|
$1,200
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S2
|
$60,000
|
$600
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant - PDXNet Supplement
|
3P30CA013696-44S3
|
$126,563
|
$1,266
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S4
|
$191,726
|
$1,917
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S5
|
$237,191
|
$2,372
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-44S6
|
$246,815
|
$2,468
|
SCHWARTZ, GARY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Ovarian Cancer for this search: $120,788,374
|